Experienced in Hyperparathyroidism

Dr. Ronald H. Chochinov

Endocrinology
168 N Brent St, Suite 405, 
Ventura, CA 
Experienced in Hyperparathyroidism
168 N Brent St, Suite 405, 
Ventura, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ronald Chochinov is an Endocrinologist in Ventura, California. Dr. Chochinov is rated as an Experienced provider by MediFind in the treatment of Hyperparathyroidism. His top areas of expertise are Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), Maturity Onset Diabetes of the Young, and Obesity in Children.

His clinical research consists of participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

168 N Brent St, Suite 405, Ventura, CA 93003

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3437943
Study Phase: Phase 2
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug
Study Drugs: LY900014, Insulin Glargine
Study Phase: Phase 3
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Completed
Publish Date: February 01, 2023
Intervention Type: Biological, Drug
Study Drugs: AG019 - Low Dose, Teplizumab, AG019 - High Dose, AG019 - Low or High Dose
Study Phase: Phase 1/Phase 2
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors
An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Drug
Study Phase: Phase 4
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors
An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors
Enrollment Status: Completed
Publish Date: August 02, 2019
Intervention Type: Device, Drug
A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly
A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 11 Less Clinical Trials
Similar Doctors
Distinguished in Hyperparathyroidism
Dr. Sheila Haji-Ali
Endocrinology
Distinguished in Hyperparathyroidism
Dr. Sheila Haji-Ali
Endocrinology

The Regents Of The University Of California

100 Medical Plaza, 
Los Angeles, CA 
 (48.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sheila Haji-Ali is an Endocrinologist in Los Angeles, California. Dr. Haji-Ali is rated as a Distinguished provider by MediFind in the treatment of Hyperparathyroidism. Her top areas of expertise are Fibrous Dysplasia, Postmenopausal Osteoporosis, Osteoporosis, and Hyperparathyroidism.

Distinguished in Hyperparathyroidism
Dr. Ines Donangelo
Endocrinology
Distinguished in Hyperparathyroidism
Dr. Ines Donangelo
Endocrinology

The Regents Of The University Of California

200 Ucla Medical Plz, 
Los Angeles, CA 
 (48.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ines Donangelo is an Endocrinologist in Los Angeles, California. Dr. Donangelo is rated as a Distinguished provider by MediFind in the treatment of Hyperparathyroidism. Her top areas of expertise are Hyperparathyroidism, Type 2 Diabetes (T2D), Juvenile Primary Osteoporosis, and Obesity in Children.

Tricia L. Westhoff
Distinguished in Hyperparathyroidism
Dr. Tricia L. Westhoff
Endocrinology
Distinguished in Hyperparathyroidism
Dr. Tricia L. Westhoff
Endocrinology
215 Pesetas Lane, 
Santa Barbara, CA 
 (30.9 miles away)
805-681-7820
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tricia Westhoff is an Endocrinologist in Santa Barbara, California. Dr. Westhoff is rated as a Distinguished provider by MediFind in the treatment of Hyperparathyroidism. Her top areas of expertise are Hypothyroidism, Type 2 Diabetes (T2D), Obesity in Children, and Thyroid Nodule.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chochinov's expertise for a condition
ConditionClose
        View All 17 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile